AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 191 min read$URGN

HC Wainwright & Co. reiterates Buy rating on UroGen Pharma, $75 price target

HC Wainwright & Co. reiterated a Buy rating on UroGen Pharma with a $75 price target, implying a 117% upside from the Oct 16 close. The FDA accepted the NDA for UGN-103, with potential approval by June 2027. Phase 3 trial data showed a 77.8% complete response rate at three months.

Original reporting
tradingview.com
Published Oct 19, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 2:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on UroGen Pharma, $75 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$URGNBullishLow
01

Why it matters

The reiteration of a Buy rating and a $75 price target could attract new buying interest, especially given the sizable upside implied.

02

Market read

Analyst upgrade with a high target may drive short‑term buying pressure in URGN, while the FDA acceptance adds longer‑term upside potential.

03

What to watch

Potential competition in the bladder cancer space and the timeline to approval (June 2027) may temper near‑term upside.

Relevance 8/10Novelty 7/10Timing: post-market today

Background

UroGen Pharma (URGN) is a clinical‑stage biotech developing intravesical therapies for bladder cancer. The analyst note highlights FDA acceptance of the NDA for UGN-103 and strong Phase 3 data.

Company-level read

Ticker impact

$URGNBullishHigh confidence
Context

HC Wainwright reiterated a Buy rating on UroGen Pharma and set a $75 price target after FDA acceptance of the UGN-103 NDA.

Expected impact

upward pressure as investors price in the new target and FDA progress.

Evidence & confidence

The rating reiteration and $75 target represent a 117% upside from the recent close, indicating strong bullish sentiment.

Market effects

Sector

Positive signal for the biotech/oncology sector as FDA acceptance may boost peer sentiment.

Regional

Limited to U.S. biotech investors; no broad regional effect.

Global

Minor global impact; primarily relevant to U.S. biotech portfolios.

Counterpoint

What could challenge this read

The target may be overly optimistic given clinical risk; investors could wait for actual approval data.

Key entities

  • analyst
    HC Wainwright & Co.

    Equity research firm that issued the Buy rating and price target.

  • company
    UroGen Pharma

    Biotech firm developing UGN-103 for bladder cancer.

Read at source← All news

StoryFDA begins review of UroGen’s UGN-103 bladder cancer treatment

Also covered by

3 outlets

Related articles

OCT 19
$URGNHighAI 8/10

UroGen Pharma Announces FDA Acceptance Of UGN-103 NDA For Review

UroGen Pharma (URGN) announced FDA acceptance of the New Drug Application for UGN-103, a treatment for recurrent low-grade bladder cancer, with a PDUFA target action date of June 14, 2027. The NDA is supported by Phase 3 UTOPIA trial data. UroGen shares rose 0.69% to $34.80 in pre-market trading.

rttnews.com1 min
OCT 19
$URGNMedAI 8/10

FDA accepts UroGen’s drug application for bladder cancer

UroGen Pharma (URGN) announced the FDA accepted its New Drug Application for UGN-103, a treatment for recurrent low-grade bladder cancer. The FDA set a target review date of June 14, 2027. The application is supported by Phase 3 trial data showing a 77.8% complete response rate at three months. UroGen holds U.S. patents for the drug through July 2044.

investing.com2 min
SEP 23
$URGNHighAI 8/10

Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?

UroGen Pharma (URGN) signed a deal with IntraGel Therapeutics, investing up to $7M for rights to develop oncology products and potentially acquire TumoCure. URGN's ZUSDURI generated $50.4M in Q2 2026 revenue, up 73% QoQ, with strong prescriber retention and patent protection extended to 2044. UGN-103 is on track for NDA submission in Q3 2026, and UGN-501 will begin Phase 1 trials in Q4 2026.

yahoo.com2 min
SEP 9
$URGNMed

UroGen Pharma general counsel sells $64,618 in shares

UroGen Pharma's (URGN) General Counsel, Jason Drew Smith, sold 1,519 shares for $64,618 and acquired 3,334 shares via restricted stock units. URGN reported Q2 2026 revenue of $72.5M, beating estimates, driven by its bladder-cancer drug ZUSDURI. Guggenheim raised its price target to $58, while H.C. Wainwright set a $75 target.

investing.com2 min